Trinity Biotech Posts Flat Q4 Revenues

Mar 07, 2019

|

NEW YORK (360Dx) — Irish diagnostics firm Trinity Biotech reported today revenues of $24.6 million for the fourth quarter of 2018, essentially unchanged from the same period a year earlier amid a drop in revenues from its clinical laboratory operations.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Breaking News

Apr

16

Featured Webinar

The Post-Vaccine COVID Testing Landscape: A Virtual Roundtable Discussion

With COVID-19 vaccines rolling out, clinical labs and test developers are preparing for changes in both demand for testing and types of testing for SARS-CoV-2.

May

10

Featured Webinar

Predicting COVID-19 Severity: Leveraging the Host Immune Response to Identify High-Risk Patients and Improve Outcomes

Amid the COVID-19 pandemic, hospitals and intensive care units around the world have been overwhelmed by unprecedented levels of demand.

May

13

Featured Webinar

Limits of Detection Matter: New Challenges for SARS-CoV-2 Diagnostics and COVID-19 Patient Management

As we pass the one-year anniversary of both the COVID-19 pandemic and the first Emergency Use Authorized SARS-CoV-2 PCR detection assays, there remains significant opportunity for clinical laboratories to advance testing and support improved patient management.

Menu

Trinity Biotech Posts Flat Q4 Revenues

To read the full story....

Breaking News

Novacyt in Dispute with UK Department of Health and Social Care Over Coronavirus Test Contract

In Brief This Week: Bio-Techne, Mologic, Caris Life Sciences, And More

BioMérieux Gets CE Mark for Three Dengue Immunoassays

Hologic to Acquire Finnish MDx Firm Mobidiag for Approximately $795M

LumiraDx to Go Public on Nasdaq Through SPAC

Roche Elecsys Anti-p53 Test for Cancer Diagnosis Earns CE Mark

The Post-Vaccine COVID Testing Landscape: A Virtual Roundtable Discussion

Predicting COVID-19 Severity: Leveraging the Host Immune Response to Identify High-Risk Patients and Improve Outcomes

Limits of Detection Matter: New Challenges for SARS-CoV-2 Diagnostics and COVID-19 Patient Management

What's Popular?

CLIA Waiver in Hand, Binx Health Targeting Retailers, Urgent Care Centers With STI Tests

LumiraDx to Go Public on Nasdaq Through SPAC

Free Rapid SARS-CoV-2 Testing Being Made Available to Everyone in England

Chembio Diagnostics Shares Rise 60 Percent on Launch of SARS-CoV-2, Influenza Test

CARB-X Commits up to $13.8M to Novel Microdevices for Point-of-Care STI Test

Sponsorships